Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2024.01.187 ↗Kurz gefasst
Leserbrief in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Fatima Rajab und 3 weiteren Autor:innen. Beteiligte Einrichtung: King Edward Medical University, Lahore, Pakistan. Electronic address: frajab258@gmail.com. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- King Edward Medical University, Lahore, Pakistan. Electronic address: frajab258@gmail.com.
- King Edward Medical University, Lahore, Pakistan.
- University of Lahore, Lahore, Pakistan.
Zitieren
APA
Rajab, F., Mujahid, A., Rajab, H., & Alvi, A. (2024). Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.01.187
Vancouver
Rajab F, Mujahid A, Rajab H, Alvi A. Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.01.187
BibTeX
@article{Rajab2024,
author = {Rajab, Fatima and Mujahid, Aleena and Rajab, Hadia and Alvi, Abdullah},
title = {Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2024.01.187}
}
EUVIMED